Journal of Child

SUBMITINFORMATION
EnglishTürkçe

Case Report


DOI :10.5222/j.child.2015.107   IUP :10.5222/j.child.2015.107    Full Text (PDF)

Rituximab Treatment of A Case with Life-Threatening Systemic Lupus Erythematosus

Cemile Pehlivanoğlu, Ilmay Bilge, Bağdagül Yavaş Aksu, Alev Yılmaz, Zeynep Nagehan Yürük Yıldırım, Yasin Yılmaz, Işın Kılıçaslan, Sevinç Emre

Systemic Lupus Erythematosus (SLE) is a heterogeneous autoinflammatory disease. Genetic and environmental multifactorial agents have been implicated in its pathophysiology. Hyperactivation of B cells has been demonstrated to play a central role in SLE pathophysiology. Steroids and immunosuppressive agents are administered in the treatment of children. Rituximab is a biologic agent developed against CD20 antigens of B cells. It has been shown that rituximab is effective in B cell-dependent autoinflammatory diseases. In this paper, we will share our experience about rituximab treatment of a pediatric case with the diagnosis of lupus erythematosus with severe complications and unresponsive to other immunosuppressive therapies.

Keywords: Systemic Lupus Erythematosus (SLE), rituximab, immunosuppressive agents
DOI :10.5222/j.child.2015.107   IUP :10.5222/j.child.2015.107    Full Text (PDF)

Yaşamı Tehdit Eden Sistemik Lupus Eritematozus Vakasında Rituksimab Tedavisi

Cemile Pehlivanoğlu, Ilmay Bilge, Bağdagül Yavaş Aksu, Alev Yılmaz, Zeynep Nagehan Yürük Yıldırım, Yasin Yılmaz, Işın Kılıçaslan, Sevinç Emre

Sistemik Lupus Eritematozus, heterojen otoinflamatuar bir hastalıktır. Patofizyolojisinde genetik nedenlerin yanında çevresel multifaktöryel etkenler suçlanmıştır. B hücrelerinin aşırı aktivasyonunun lupus patofizyolojisinde önemli rol oynadığı gösterilmiştir. Çocuklarda tedavisinde steroidler ve immunsupresif ajanlar kullanılmaktadır. Rituksimab, B lenfositlerin CD20 antijenlerine karşı geliştirilen bir biyolojik ajandır. B hücrelerine bağlı otoinflamatuvar hastalıklarda etkin olduğu gösterilmiştir. Bu makalede, ciddi komplikasyonları olan ve diğer immunsupresif tedavilere yanıt vermeyen sistemik lupus eritematozus tanılı çocuk vakasında rituksimab tedavisi deneyimi paylaşılacaktır.

Keywords: Sistemik Lupus Eritematozus, rituksimab, immunsupresif ajanlar

PDF View

References

  • 1. Mir S, Keskinoğlu A. Çocukluk çağı lupus nefriti izleminde anti-dsDNA düzeyi. Ege Tıp Dergisi 2003;42(1):19-24. google scholar
  • 2. Makay B, Ünsal E. Jüvenil sistemik lupus eritematozus. Klinik Gelişim 2006;19(1):24-33. google scholar
  • 3. Livingston B, Bonner A, Pope J. Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus 2011;20(13): 1345-55. http://dx.doi.org/10.1177/0961203311416694 google scholar
  • 4. Vachvanichsanong P, McNeil E. Pediatric lupus nephritis: more options, more chances? Lupus 2013;22(6): 545-53. http://dx.doi.org/10.1177/0961203313485490 google scholar
  • 5. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 2012;64(4):1215-26. http://dx.doi.org/10.1002/art.34359 google scholar
  • 6. Pinto LF, Velásquez CJ, Prieto C, Mestra L, Forero E, Márquez JD. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus. Lupus 2011;20(11):1219-26. http://dx.doi.org/10.1177/0961203311409273 google scholar
  • 7. Davies RJ, Sangle SR, Jordan NP, Aslam L, Lewis MJ, Wedgwood R et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus 2013; 22(6):574-82. http://dx.doi.org/10.1177/0961203313483376 google scholar
  • 8. Trachana M, Koutsonikoli A, Farmaki E, Printza N, Tzimouli V, Papachristou F. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece. Rheumatol Int 2013;33(3):809-13. http://dx.doi.org/10.1007/s00296-011-2239-6 google scholar
  • 9. Willems M, Haddad E, Niaudet P, Koné-Paut I, Bensman A, Cochat P et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006;148(5):623-27. http://dx.doi.org/10.1016/j.jpeds.2006.01.041 google scholar
  • 10. Lehman TJ, Singh C, Ramanathan A, Alperin R, Adams A, Barinstein L et al. Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol Online J 2014; 12:3. http://dx.doi.org/10.1186/1546-0096-12-3 google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Pehlivanoğlu, C., Bilge, I., Yavaş Aksu, B., Yılmaz, A., Yürük Yıldırım, Z.N., Yılmaz, Y., Kılıçaslan, I., & Emre, S. (2015). Rituximab Treatment of A Case with Life-Threatening Systemic Lupus Erythematosus. Journal of Child, 15(3), 107-110. https://doi.org/10.5222/j.child.2015.107


AMA

Pehlivanoğlu C, Bilge I, Yavaş Aksu B, Yılmaz A, Yürük Yıldırım Z N, Yılmaz Y, Kılıçaslan I, Emre S. Rituximab Treatment of A Case with Life-Threatening Systemic Lupus Erythematosus. Journal of Child. 2015;15(3):107-110. https://doi.org/10.5222/j.child.2015.107


ABNT

Pehlivanoğlu, C.; Bilge, I.; Yavaş Aksu, B.; Yılmaz, A.; Yürük Yıldırım, Z.N.; Yılmaz, Y.; Kılıçaslan, I.; Emre, S. Rituximab Treatment of A Case with Life-Threatening Systemic Lupus Erythematosus. Journal of Child, [Publisher Location], v. 15, n. 3, p. 107-110, 2015.


Chicago: Author-Date Style

Pehlivanoğlu, Cemile, and Ilmay Bilge and Bağdagül Yavaş Aksu and Alev Yılmaz and Zeynep Nagehan Yürük Yıldırım and Yasin Yılmaz and Işın Kılıçaslan and Sevinç Emre. 2015. “Rituximab Treatment of A Case with Life-Threatening Systemic Lupus Erythematosus.” Journal of Child 15, no. 3: 107-110. https://doi.org/10.5222/j.child.2015.107


Chicago: Humanities Style

Pehlivanoğlu, Cemile, and Ilmay Bilge and Bağdagül Yavaş Aksu and Alev Yılmaz and Zeynep Nagehan Yürük Yıldırım and Yasin Yılmaz and Işın Kılıçaslan and Sevinç Emre. “Rituximab Treatment of A Case with Life-Threatening Systemic Lupus Erythematosus.” Journal of Child 15, no. 3 (Apr. 2024): 107-110. https://doi.org/10.5222/j.child.2015.107


Harvard: Australian Style

Pehlivanoğlu, C & Bilge, I & Yavaş Aksu, B & Yılmaz, A & Yürük Yıldırım, ZN & Yılmaz, Y & Kılıçaslan, I & Emre, S 2015, 'Rituximab Treatment of A Case with Life-Threatening Systemic Lupus Erythematosus', Journal of Child, vol. 15, no. 3, pp. 107-110, viewed 25 Apr. 2024, https://doi.org/10.5222/j.child.2015.107


Harvard: Author-Date Style

Pehlivanoğlu, C. and Bilge, I. and Yavaş Aksu, B. and Yılmaz, A. and Yürük Yıldırım, Z.N. and Yılmaz, Y. and Kılıçaslan, I. and Emre, S. (2015) ‘Rituximab Treatment of A Case with Life-Threatening Systemic Lupus Erythematosus’, Journal of Child, 15(3), pp. 107-110. https://doi.org/10.5222/j.child.2015.107 (25 Apr. 2024).


MLA

Pehlivanoğlu, Cemile, and Ilmay Bilge and Bağdagül Yavaş Aksu and Alev Yılmaz and Zeynep Nagehan Yürük Yıldırım and Yasin Yılmaz and Işın Kılıçaslan and Sevinç Emre. “Rituximab Treatment of A Case with Life-Threatening Systemic Lupus Erythematosus.” Journal of Child, vol. 15, no. 3, 2015, pp. 107-110. [Database Container], https://doi.org/10.5222/j.child.2015.107


Vancouver

Pehlivanoğlu C, Bilge I, Yavaş Aksu B, Yılmaz A, Yürük Yıldırım ZN, Yılmaz Y, Kılıçaslan I, Emre S. Rituximab Treatment of A Case with Life-Threatening Systemic Lupus Erythematosus. Journal of Child [Internet]. 25 Apr. 2024 [cited 25 Apr. 2024];15(3):107-110. Available from: https://doi.org/10.5222/j.child.2015.107 doi: 10.5222/j.child.2015.107


ISNAD

Pehlivanoğlu, Cemile - Bilge, Ilmay - Yavaş Aksu, Bağdagül - Yılmaz, Alev - Yürük Yıldırım, ZeynepNagehan - Yılmaz, Yasin - Kılıçaslan, Işın - Emre, Sevinç. “Rituximab Treatment of A Case with Life-Threatening Systemic Lupus Erythematosus”. Journal of Child 15/3 (Apr. 2024): 107-110. https://doi.org/10.5222/j.child.2015.107



TIMELINE


Published Online31.12.2015

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.